![](/img/cover-not-exists.png)
57P Benefit of CDK4/6 inhibitors beyond PIK3CA mutations in metastatic breast cancer patients
Tolosa Ortega, P., Cejalvo, J.M., Moragon Terencio, S., Carril-Ajuria, L., Bermejo, B., Ruiz, Ã., Hernando Melia, C., Sánchez-Torre, A., MartÃnez, M.T., Herrera, M., Gambardella, V., Lema, L., RodaVolume:
31
Journal:
Annals of Oncology
DOI:
10.1016/j.annonc.2020.03.191
Date:
May, 2020
File:
PDF, 85 KB
2020